Docetaxel vs. Docetaxel-Gemcitabine in Breast Cancer

• Status: Completed
• Trial end date: 2009-04-01
• Target enrollment: 0
• Participant gender: Female

Summary

Randomized,non-blinded,multi-center study in patients with metastatic breast cancer.Patients will be treated with docetaxel or docetaxel-gemcitabine.

Aim of the study is to assess the optimal dosage and safety in this setting.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Docetaxel; Gemcitabine

Criteria

Inclusion Criteria:

• histologically verified diagnosis of breast carcinoma, at first diagnosis

• restricted previous adjuvant chemotherapy (completed >6 months prior the study)

• measurable and/or non-measurable disease

• previous radiotherapy is allowed if:terminated at least 10 days prior the sudy therapy, at least one target lesion for evaluation of tumor response has not been irradiated

• performance status 0-2 (WHO, Zubrod)

• adequate bone marrow reserve defined

• adequate liver / renal functions defined

Exclusion Criteria:

• any prior systematic chemotherapy for metastatic breast cancer

• expected survival time less than 12 weeks

• past or current history of malignant neoplasm other than breast carcinoma

• except for cured non-melanoma skin cancer or curatively treated in situ carcinoma of the cervix uteri

• known brain metastases/leptomeningeal involvement

• active uncontrolled infection

• symptomatic peripheral neuropathy > grade 2 according to NCI

• patients whose lesions are assessable only by radionuclide scan or patients with sclerotic bone lesions as the only site of disease

• concomitant illness that is contraindication to the use of corticosteroids

• other concomitant serious illness or medical condition, which may worsen due to the treatment